4-烯丙基-1-哌嗪甲酰胺 | 157459-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 4-烯丙基-1-哌嗪甲酰胺
• 英文名称: 4-(Prop-2-en-1-yl)piperazine-1-carboxamide
• 英文别名: 4-prop-2-enylpiperazine-1-carboxamide
• CAS: 157459-51-3
• 化学式: C₈H₁₅N₃O
• 分子量: 169.22
• InChiKey: VRGLKMGVFZMMKI-UHFFFAOYSA-N

物化性质

• 沸点：
  268.6±50.0 °C(Predicted)
• 密度：
  1.083±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  49.6
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Trisubstituted pyrimidines
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US20030134838A1

  公开（公告）日：2003-07-17

  The present invention relates to trisubstituted pyrimidines of formula 1 wherein R a to R e are defined as in claim 1, which are suitable for the treatment of illnesses in which &bgr;-amyloid modulators have a therapeutic benefit, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

  本发明涉及式1的三取代嘧啶，其中R至Re的定义如权利要求1中所述，适用于治疗β-淀粉样蛋白调节剂具有治疗效益的疾病，用于制备具有上述特性的药物组合物的用途，以及其制备方法。
• [EN] ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF SUBSTITUTED NORTROPANES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE<br/>[FR] DÉRIVÉS ARYLE ET HÉTÉROARYLCARBONYLE DE NORTROPANES SUBSTITUÉS, MÉDICAMENTS CONTENANT DE TELS COMPOSÉS ET LEURS APPLICATIONS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010023161A1

  公开（公告）日：2010-03-04

  The present invention relates to compounds defined by formula (I) wherein the groups R1 and R2 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

  本发明涉及由式（I）定义的化合物，其中基团R1和R2如权利要求1中定义，具有有价值的药理活性。特别是这些化合物是11β-羟基类固醇脱氢酶（HSD）1的抑制剂，因此适用于治疗和预防可以通过抑制该酶而受影响的疾病，如代谢性疾病，特别是2型糖尿病、肥胖和脂质代谢异常。
• Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases
  申请人：Bower Justin Fairfield

  公开号：US20080287453A1

  公开（公告）日：2008-11-20

  A compound of formula (I) P—W—C(═X)-L-Q   (I) wherein P is an optionally substituted aryl or heteroaryl group; W is an optionally substituted 6 or 7-membered aliphatic ring comprising ring atoms Y 1 and Y 2 independently selected from Oxygen and Nitrogen, X is selected from Oxygen, Nitrogen and Sulphur; L is an optional C 1-4 linker; and Q is an optionally substituted 4-7 membered aliphatic ring: for use in the treatment of chemokine mediated diseases or disorders.

  化合物式为(I)P—W—C(═X)-L-Q  (I)的化合物，其中P是一种可选取的取代芳基或杂环芳基基团；W是一种可选取的6或7成员的脂环，包括环原子Y1和Y2，其独立地选自氧和氮，X选自氧、氮和硫；L是可选的C1-4连接基；Q是一种可选取的4-7成员的脂环；用于治疗趋化因子介导的疾病或疾病的化合物。
• 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES
  申请人：Otsuka Pharmaceutical Company, Limited

  公开号：EP1740574B1

  公开（公告）日：2007-06-27
• PIPERAZINE COMPOUNDS USEFUL AS ANTAGONISTS OF C-C CHEMOKINES (CCR2B AND CCR5) FOR THE TREATMENT OF INFLAMMATORY DISEASES
  申请人：AstraZeneca AB

  公开号：EP1966187A1

  公开（公告）日：2008-09-10